Non-steroidal anti-inflammatory drugs in the carcinogenesis of the gastrointestinal tract

Pharmaceuticals

Volumn 3, Issue 8, 2010, Pages 2495-2516

  Compare, Debora ^a   Nardone, Olga ^a   Nardone, Gerardo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Colorectal cancer; Cyclooxygenase 2; Esophageal cancer; Gastric cancer; Non steroidal anti inflammatory drugs

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; APC PROTEIN; CELECOXIB; CYCLINE; CYTOKINE; DEXAMETHASONE; DNA; FAS ANTIGEN; GASTRIN; GROWTH FACTOR; IBUPROFEN; INDOMETACIN; KETOPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; ROFECOXIB; SCATTER FACTOR; SULINDAC; TILMACOXIB; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG; VALDECOXIB;

ADRENAL CORTEX INSUFFICIENCY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MORTALITY; CARCINOGENESIS; CELL PROLIFERATION; CHEMICAL INJURY; CLINICAL TRIAL; COLON POLYPOSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DRUG DOSE COMPARISON; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; ESOPHAGEAL ADENOCARCINOMA; FAMILIAL COLON POLYPOSIS; HELICOBACTER PYLORI; HOMEOSTASIS; HUMAN; INFECTION; INFLAMMATION; INFLAMMATORY CELL; KIDNEY DISEASE; MACROPHAGE; MALIGNANT TRANSFORMATION; NEUTROPHIL; NONHUMAN; PROSTAGLANDIN SYNTHESIS; RECTUM POLYP; SKIN INJURY; STOMACH CANCER; STOMACH CARCINOMA; STOMACH HEMORRHAGE; STOMACH ULCER; TISSUE INJURY; UPPER GASTROINTESTINAL BLEEDING;

EID: 77955589143     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3082495     Document Type: Article

References (143)

1. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 2001, 357, 539-545.
2. Philip, M.; Rowley, D.A.; Schreiber, H. Inflammation as a tumour promoter in cancer induction. Semin. Cancer Biol. 2004, 14, 433-439.
3. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860-867.
4. Colotta, F.; Allavena, P.; Sica, A.; Garlanda, C.; Mantovani, A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30, 1073-1081.
5. Itzkowitz, S.H.; Yio, X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287, G7-17.
6. Seril, D.N.; Lia, J.; Yang, G.Y.; Yang, C.S. Oxidative stress and ulcerative colitis associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003, 24, 353-362.
7. Macarthur, M.; Hold, G.L.; El-Omar, E.M. Inflammation and cancer. II. Role of chronic inflammation and cytokine polymorphisms in the pathogenesis of gastrointestinal malignancy. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286, G515-G520.
8. Whitcomb, D.C. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287, G315-G319.
9. Cordon-Cardo, C.; Prives, C. Commentary: at the crossroads of inflammation and tumourigenesis. J. Exp. Med. 1999, 190, 1367-1370.
10. Nathan, C. Points of control in inflammation. Nature 2002, 420, 846-852.
11. Maeda, H.; Akaike, H. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry 1998, 63, 854-865.
12. Fulton, A.M.; Loveless, S.E.; Heppner, G.H. Mutagenic activity of tumourassociated macrophages in Salmonella typhimurium strains TA98 and TA100. Cancer Res. 1984, 44, 4308-4311.
13. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4, 71-78.
14. Coussens, L.M.; Werb, Z. Inflammatory cells and cancer: think different! J. Exp. Med. 2001, 193, F23-26.
15. Mantovani, A.; Bottazzi, B.; Colotta, F.; Sozzani, S.; Ruco, L. The origin and function of tumourassociated macrophages. Immunol. Today 1992, 13, 265-270.
16. Mantovani, A.; Bussolino, F.; Dejana, E. Cytokine regulation of endothelial cell function. FASEB J. 1992, 6, 2591-2599.
17. Coussens, L.M.; Tinkle, C.L.; Hanahan, D.; Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103, 481-490.
18. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4, 11-22.
19. Negus, R.P.M.; Stamp, G.W.H.; Relf, M.G.; Burke, F.; Malik, S.T.; Bernasconi, S.; Allavena, P.; Sozzani, S.; Mantovani, A.; Balkwill, F.R. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 1995, 95, 2391-2396.
20. Luboshits, G.; Shina, S.; Kaplan, O.; Engelberg, S.; Nass, D.; Lifshitz-Mercer, B.; Chaitchik, S.; Keydar, I.; Ben-Baruch, A. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999, 59, 4681-4687.
21. Daniel, D.; Meyer-Morse, N.; Bergsland, E.K.; Dehne, K.; Coussens, L.M.; Hanahan, D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med. 2003, 197, 1017-1028.
22. Wilson, J.; Balkwill, F. The role of cytokines in the epithelial cancer microenvironment. Semin. Cancer Biol. 2002, 12, 113-120.
23. Ardestani, S.K.; Inserra, P.; Solkoff, D.; Watson, R.R. The role of cytokines and chemokines on tumour progression: a review. Cancer Detect. Prev. 1999, 23, 215-225.
24. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
25. Herschman, H.R. Prostaglandin synthase 2. Biochim. Biophys. Acta 1996, 1299, 125-140.
26. Diaz, B.L.; Arm, J.P. Phospholipase A2. Prostag. Leukotr. Ess. 2003, 69, 87-97.
27. Reddy, S.T.; Herschman, H.R. Ligand-induced prostaglandin synthesis requires expression of the TIS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J. Biol. Chem. 1994, 269, 15473-15480.
28. Chandrasekharan, N.V.; Dai, H.; Roos, K.L.; Evanson, N.K.; Tomsik, J.; Elton, T.S.; Simmons, D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 2002, 99, 13926-13931.
29. Fosslien, E. Biochemistry of cyclooxygenase COX-2 inhibitors and molecular pathology of COX- 2 in neoplasia. Crit. Rev. Clin. Lab. Sci. 2000, 37, 431-502.
30. Saukkonen, K.; Rintahaka, J.; Sivula, A.; Buskens, C.J.; Van Rees, B.P.; Rio, M.C.; Haglund, C.; van Lanschot, J.J.; Offerhaus, G.J.; Ristimaki, A. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003, 111, 915-925.
31. Hata, A.N.; Breyer, R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 2004, 103, 147-166.
32. Kota, B.P.; Huang, T.H.; Roufogalis, B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res. 2005, 51, 85-94.
33. Leone, V.; di Palma, A.; Ricchi, P.; Acquaviva, F.; Giannouli, M.; Di Prisco, A.M.; Iuliano, F.; Acquaviva, A.M. PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293, G673-681.
34. Pradono, P.; Tazawa, R.; Maemondo, M.; Tanaka, M.; Usui, K.; Saijo, Y.; Hagiwara, K.; Nukiwa, T. Gene transfer of thromboxane A(2) synthase and prostaglandin I (2) synthase antithetically altered tumour angiogenesis and tumour growth. Cancer Res. 2002, 62, 63-66.
35. Yokoyama, I.; Hayashi, S.; Kobayashi, T.; Negita, M.; Yasutomi, M.; Uchida, K.; Takagi, H. Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. Res. Exp. Med. 1995, 195, 209-215.
36. Wang, D.; Buchanan, F.G.; Wang, H.; Dey, S.K.; DuBois, R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 2005, 65, 1822-1829.
37. Cao, Y.; Prescott, S.M. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol. 2002, 190, 279-286.
38. Sheng, H.; Shao, J.; Morrow, J.D., Beauchamp, R.D.; DuBois, R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998, 58, 362-366.
39. Poligone, B.; Baldwin, A.S. Positive and negative regulation of NF-kappa B by COX-2: roles of different prostaglandins. J. Biol. Chem. 2001, 276, 38658-38664.
40. Nzeako, U.C.; Guicciardi, M.E.; Yoon, J.H.; Bronk, S.F.; Gores, G.J. COX-2 inhibits Fasmediated apoptosis in cholangiocarcinoma cells. Hepatology 2002, 35, 552-559.
41. Pasricha, P.J.; Bedi, A., O'Connor; K., Rashid, A.; Akhtar, A.J.; Zahurak, M.L.; Piantadosi, S.; Hamilton, S.R.; Giardiello, F.M. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995, 109, 994-998.
42. Boolbol, S.K.; Dannenberg, A.J.; Chadburn, A.; Martucci, C.; Guo, X.J.; Ramonetti, J.T.; Abreu- Goris, M.; Newmark, H.L.; Lipkin, M.L.; De Cosse, J.J.; Bertagnolli, M.M. Cyclooxygenase-2 overexpression and tumour formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996, 56, 2556-2560.
43. Mahmoud, N.N.; Bilinski, R.T.; Churchill, M.R.; Edelmann; W.; Kucherlapati; R.; Bertagnolli, M.M. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. Cancer Res. 1999, 59, 353-359.
44. Mahmoud, N.N.; Dannenberg, A.J.; Mestre, J.; Bilinski, R.T.; Churchill, M.R.; Martucci, C.; Newmark, H.; Bertagnolli, M.M. Aspirin prevents tumours in a murine model of familial adenomatous polyposis. Surgery 1998, 24, 225-231.
45. Samaha, H.S.; Kelloff, G.J.; Steele, V.; Rao, C.V.; Reddy, B.S. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. 1997, 57, 1301-1305.
46. Uefuji, K.; Ichikura, T.; Shinomiya, N.; Mochizuki, H. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res. 2000, 20, 4279-4284.
47. Li, M.; Lotan, R.; Levin, B.; Tahara, E.; Lippman, S.M.; Xu, X.C. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 545-549.
48. Grösch, S.; Tegeder, I.; Niederberger, E.; Bräutigam, L.; Geisslinger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15, 2742-2744.
49. Molina, M.A.; Sitja-Arnau, M.; Le moine, M.G.; Frazier, M.L.; Sinicrope, F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999, 59, 4356-4362.
50. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93, 705-716.
51. Trompezinski, S.; Pernet, I.; Schmitt, D.; Viac, J. UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm. Res. 2001, 50, 422-427.
52. Pai, R.; Szabo, I.L.; Soreghan, B.A.; Atay, S.; Kawanaka, H.; Tarnawski, A.S. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem. Biophys. Res. Commun. 2001, 286, 923-928.
53. Kage, K.; Fujita, N.; Oh-hara, T.; Ogata, E.; Fujita, T.; Tsuruo, T. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem. Biophys. Res. Commun. 1999, 254, 259-263.
54. Salcedo, R.; Zhang, X.; Young, H.A.; Michael, N.; Wasserman, K.; Ma, W.H.; Martins-Green, M.; Murphy, W.J.; Oppenheim, J.J. Angiogenic effects of prostaglandin E2 are mediated by upregulation of CXCR4 on human microvascular endothelial cells. Blood 2003, 102, 1966-1977.
55. Kaidi, A.; Qualtrough, D.; Williams, A.C.; Paraskeva, C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumour cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 2006, 66, 6683-6691.
56. Dormond, O.; Foletti, A., Paroz; C., Rüegg, C. NSAIDs inhibit alpha V beta 3integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med. 2001, 7, 1041-1047.
57. Knutson, K.L.; Disis, M.L. Tumour antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 2005, 54, 721-728.
58. Harris, S.G.; Padilla, J.; Koumas, L.; Ray, D.; Phipps, R.P. Prostaglandins as modulators of immunity. Trends Immunol. 2002, 23, 144-150.
59. Della Bella, S.; Molteni, M.; Compasso, S.; Zulian, C.; Vanoli, M.; Scorza, R. Differential effect of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot. Essent. Fatty Acids 1997, 56, 177-184.
60. Holla, V.R.; Wang, D.; Brown, J.R.; Mann, J.R.; Katkuri, S.; DuBois, R.N. Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J. Biol. Chem. 2005, 280, 476-483.
61. Stolina, M.; Sharma, S.; Lin, Y.; Dohadwala, M.; Gardner, B.; Luo, J.; Zhu, L.; Kronenberg, M.; Miller, P.W.; Portanova, J.; Lee, J.C.; Dubinett, S.M. Specific inhibition of cyclooxygenase 2 restores antitumour reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 2000, 164, 361-370.
62. Yao, M.; Kargman, S.; Lam, E.C.; Kelly, C.R.; Zheng, Y.; Luk, P.; Kwong, E.; Evans, J.F.; Wolfe, M.M. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 2003, 63, 586-592.
63. Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Nat. Acad. Sci. USA 1994, 91, 12013-12017.
64. Singh, G.; Ramey, D.R.; Morfeld, D.; Fries, J.F. Comparative toxicity of non-steroidal antiinflammatory agents. Pharmacol. Ther. 1994, 62, 175-191.
65. Bjarnason, I.; Macpherson, A.J.S. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol. Ther. 1994, 62, 145-157.
66. Allison, M.C.; Howatson, A.G.; Torrance, C.J.; Lee, F.D.; Russell, R.I. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs, N. Engl. J. Med. 1992, 327, 749-754.
67. Langman, M.J.S.; Weil, J.; Wainwright, P.; Lawson, D.H.; Rawlins, M.D.; Logan, R.F.A.; Murphy, M.; Vessey, M.P.; Colin-Jones, D.G. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343, 1075-1078.
68. Masferrer, J.L.; Seibert, K. Regulation of prostaglandin synthesis by glucocorticoids. Receptor 1994, 4, 25-30.
69. Masferrer, J.L.; Reddy, S.T.; Zweifel, B.S.; Seibert, K.; Needleman, P.; Gilbert, R.S.; Herschman, H.R. In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J. Pharmacol. Exp. Ther. 1994, 270, 1340-1344.
70. Fitzgerald, G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 2004, 351, 1709-1711.
71. Topol, E.J. Failing the public health: rofecoxib, Merck, and the FDA. N. Engl. J. Med. 2004, 351, 1707-1709.
72. Morris, C.D.; Armstrong, G.R.; Bigley, G.; Green, H.; Attwood, S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 2001, 96, 990-996.
73. Shirvani, V.N.; Ouatu-Lascar, R.; Kaur, B.S.; Omary, M.B.; Triadafilopoulos, G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000, 118, 487-496.
74. Zhang, F.; Altorki, N.K.; Wu, Y.C.; Soslow, R.A.; Subbaramaiah, K.; Dannenberg, A.J. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001, 121, 1391-1399.
75. Abnet, C.C.; Freedman, N.D.; Kamangar, F.; Leitzmann, M.F.; Hollenbeck, A.R.; Schatzkin, A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br. J. Cancer 2009, 100, 551-557.
76. Hughes, S.J.; Nambu, Y.; Soldes, O.S.; Hamstra, D.; Rehemtulla, A.; Iannettoni, M.D.; Orringer, M.B.; Beer, D.G. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997, 57, 5571-5578.
77. Tsujii, M.; DuBois, R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83, 493-501.
78. Buttar, N.S.; Wang, K.K.; Leontovich, O.; Westcott, J.Y.; Pacifico, R.J.; Anderson, M.A.; Krishnadath, K.K.; Lutzke, L.S.; Burgart, L.J. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122, 1101-1112.
79. Kaur, B.S.; Khamnehei, N.; Iravani, M.; Namburu, S.S.; Lin, O.; Triadafilopoulos, G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002, 123, 60-67.
80. Souza, R.F.; Shewmake, K.; Beer, D.G.; Cryer, B.; Spechler, S.J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000, 60, 5767-5772.
81. Buttar, N.S.; Wang, K.K.; Anderson, M.A.; Dierkhising, R.A.; Pacifico, R.J.; Krishnadath, K.K.; Lutzke, L.S. The effect of selective cyclooxygenase-inhibition in Barrett's esophagus epithelium: an in vitro study. J. Natl. Cancer Inst. 2002, 94, 422-429.
82. Li, Z.; Shimada, Y.; Kawabe, A.; Sato, F.; Maeda, M.; Komoto, I.; Hong, T.; Ding, Y.; Kaganoi, J.; Imamura, M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumourigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 2001, 22, 547-551.
83. Heath, E.I.; Canto, M.I.; Piantadosi, S.; Montgomery, E.; Weinstein, W.M.; Herman, J.G.; Dannenberg, A.J.; Yang, V.W.; Shar, A.O.; Hawk, E.; Forastiere, A.A. Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J. Natl. Cancer Inst. 2007, 99, 545-557.
84. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
85. Correa, P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992, 52, 6735-6740.
86. Hofman, P.; Waidner, B.; Hofman, V.; Bereswill, S.; Brest, P.; Kist, M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2004, 9 (Suppl. 1), 15-22.
87. Romano, M.; Ricci, V.; Memoli, A.; Tuccillo, C.; Di Popolo, A.; Sommi, P.; Acquaviva, A.M.; Del Vecchio Blanco, C.; Bruni, C.B.; Zarrilli, R. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J. Biol. Chem. 1998, 273, 28560-28563.
88. Nardone, G.; Rocco, A.; Vaira, D.; Staibano, S.; Budillon, A.; Tatangelo, F.; Sciulli, M.G.; Perna, F.; Salvatore, G.; Di Benedetto, M.; De Rosa, G.; Patrignani, P. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J. Pathol. 2004, 202, 305-312.
89. Sung, J.J.; Leung, W.K.; Go, M.Y.; To, K.F.; Cheng, A.S.; Ng, E.K.; Chan, F.K. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. 2000, 157, 729-735.
90. Ristimaki, A.; Honkanen, N.; Jankala, H.; Sipponen, P.; Harkonen, M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997, 57, 1276-1280.
91. Sun, W.H.; Yu, Q.; Shen, H.; Ou, X.L.; Cao, D.Z.; Yu, T.; Qian, C.; Zhu, F.; Sun, Y.L.; Fu, X.L.; Su, H. Roles of Helicobactor pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J. Gastroenterol. 2004 10, 2809-2813.
92. Saukkonen, K.; Nieminen, O.; van Rees, B.; Vilkki, S.; Harkonen, M.; Juhola, M.; Mecklin, J.P.; Sipponen, P.; Ristimaki, A. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin. Cancer Res. 2001, 7, 1923-1931.
93. Yamagata, R.; Shimoyama, T.; Fukuda, S.; Yoshimura, T.; Tanaka, M.; Munakata, A. Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur. J. Gastroenterol. Hepatol. 2002, 14, 359-363.
94. Uefuji, K.; Ichikura, T.; Mochizuki, H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J. Surg. Oncol. 2001, 76, 26-30.
95. Xue, Y.W.; Zhang, Q.F.; Zhu, Z.B.; Wang, Q.; Fu, S.B. Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma. World J. Gastroenterol. 2003, 9, 250-253.
96. Murata, H.; Kawano, S.; Tsuji, S.; Tsuji, M.; Sawaoka, H.; Kimura, Y.; Shiozaki, H.; Hori, M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am. J. Gastroenterol. 1999, 94, 451-455.
97. Yamamoto, H.; Itoh, F.; Fukushima, H.; Hinoda, Y.; Imai, K. Overexpression of Cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. Int. J. Cancer. 1999, 84, 400-403.
98. Joo, Y.E.; Oh, W.T.; Rew, J.S.; Park, C.S.; Choi, S.K.; Kim, S.J. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 2002, 66, 222-229.
99. Konturek, P.C.; Kania, J.; Kukharsky, V.; Ocker, S.; Hahn, E.G.; Konturek, S.J. Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. J. Physiol. Pharmacol. 2003, 54, 17-32.
100. Konturek, P.C.; Konturek, S.; Sulekova, Z.; Meixner, H.; Bielanski, W.; Starzynska, T.; Karczewska, E.; Marlicz, K.; Stachura, J.; Hahn, E.G. Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment. Pharmacol. Ther. 2001, 15, 989-999.
101. Konturek, P.C.; Konturek, S.J.; Bielanski, W.; Karczewska, E.; Pierzchalski, P.; Duda, A.; Starzynska, T.; Marlicz, K.; Popiela, T.; Hartwich, A.; Hahn, E.G. Role of gastrin in gastric cancerogenesis in Helicobacter pylori infected humans. J. Physiol. Pharmacol. 1999, 50, 857-873.
102. Konturek, S.J.; Konturek, P.C.; Bielanski, W.; Karczewska, E.; Zuchowicz, M.; Hartwich, A.; Rehfeld, J.F.; Goetze, J.P.; Hahn, E.G. Serum progastrin and its products, gastric acid secretion and serum pepsinogen I in gastric cancer. Digestion 2003, 68, 169-177.
103. Konturek, P.C.; Konturek, S.J.; Bielanski, W.; Kania, J.; Zuchowicz, M.; Hartwich, A.; Rehfeld, J.F.; Hahn, E.G. Influence of COX-2 inhibition by rofecoxib on serum and tumour progastrin and gastrin levels and expression of PPAR gamma and apoptosisrelated proteins in gastric cancer patients. Dig. Dis. Sci. 2003, 48, 2005-2017.
104. Fosslien, E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 2000, 30, 3-21.
105. Koki, A.T.; Leahy, K.M.; Masferrer, J.L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs 1999, 8, 1623-1638.
106. Fosslien, E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann. Clin. Lab. Sci. 2001, 31, 325-348.
107. Fujiwara, Y.; Tarnawski, A.; Fujiwara, K.; Arakawa, T.; Kobayashi, K. Inhibitory effects of indomethacin on growth and proliferation of gastric carcinoma cells KATO III. J. Physiol. Pharmacol. 1993, 44, 147-153.
108. Sawaoka, H.; Kawano, S.; Tsuji, S.; Gunawan, E.S.; Takei, Y.; Nagano, K.; Hori, M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 1998, 274, G1061-G1067.
109. Fujiwara, Y.; Schmassmann, A.; Arakawa, T.; Halter, F.; Tarnawski, A. Indomethacin interferes with epidermal growth factor binding and proliferative response of gastric KATO III cells. Digestion 1995, 56, 364-369.
110. Nam, K.T.; Hahm, K.B.; Oh, S.Y.; Yeo, M.; Han, S.U.; Ahn, B.; Kim, Y.B.; Kang, J.S.; Jang, D.D.; Yang, K.H.; Kim, D.Y. The selective cyclooxy- genase-2 inhibitor nimesulide prevents Helicobacter pyloriassociated gastric cancer development in a mouse model. Clin. Cancer Res. 2004, 10, 8105-8113.
111. Oshima, H.; Oshima, M.; Inaba, K.; Taketo, M.M. Hyperplastic gastric tumours induced by activated macrophage in COX-2/mPGES-1 transgenic mice. EMBO J. 2004, 23, 1669-1678.
112. Miwa, K.; Hasegawa, H.; Fujimura, T.; Matsumoto, H.; Miyata, R.; Kosaka, T.; Miyazaki, I.; Hattori, T. Duodenal reflux through the pylorus induces gastric adenocarcinoma in the rat. Carcinogenesis 1992, 13, 2313-2316.
113. Thun, M.J.; Namboodiri, M.M.; Calle, E.E.; Flanders, W.D.; Heath, C.W., Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53, 1322-1327.
114. Coogan, P.F.; Rosenberg, L.; Palmer, J.R.; Strom, B.L.; Zauber, A.G.; Stolley, P.D.; Shapiro, S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 119-123.
115. Farrow, D.C.; Vaughan, T.L.; Hansten, P.D.; Stanford, J.L.; Risch, H.A.; Gammon, M.D.; Chow, W.H.; Dubrow, R.; Ahsan, H.; Mayne, S.T.; Schoenberg, J.B.; West, A.B.; Rotterdam, H.; Fraumeni, J.F., Jr.; Blot, W.J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1998, 7, 97-102.
116. Das, D.; Chilton, A.P.; Jankowski, J.A. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009, 181, 161-169.
117. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M.J. Cancer statistics, 2006. CA Cancer J. Clin. 2006, 56, 106-130.
118. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumourigenesis. Cell 1990 61, 759-767.
119. Sinicrope, F.A.; Gill, S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004, 23, 63-75.
120. DuBois, R.N.; Radhika, A.; Reddy, B.S.; Entingh, A.J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumours. Gastroenterology 1996, 110, 1259-1262.
121. Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803-809.
122. Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107, 1183-1188.
123. Karnes, W.E., Jr.; Shattuck-Brandt, R.; Burgart, L.J.; Du Bois, R.N.;Tester, D.J.; Cunningham, J.M.; Kim, C.Y.; McDonnell, S.K.; Schaid, D.J.; Thibodeau, S.N. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res. 1998, 58, 5473-5477.
124. Dimberg, J.; Samuelsson, A.; Hugander, A.; Soderkvist, P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999, 45, 730-732.
125. Chapple, K.S.; Cartwright, E.J.; Hawcroft, G.; Tisbury, A.; Bonifer, C.; Scott, N.; Windsor, A.C.; Guillou, P.J.; Markham, A.F.; Coletta, P.L.; Hull, M.A. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am. J. Pathol. 2000, 156, 545-553.
126. Shattuck-Brandt, R.L.; Varilek, G.W.; Radhika, A.; Yang, F.; Washington, M.K.; DuBois, R.N. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10 (-/-) mice. Gastroenterology 2000, 118, 337-345.
127. Tomozawa, S.; Tsuno, N.H.; Sunami, E.; Hatano, K.; Kitayama, J.; Osada, T.; Saito, S.; Tsuruo, T.; Shibata, Y.; Nagawa, H. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br. J. Cancer 2000, 83, 324-328.
128. Tsujii, M.; Kawano, S.; DuBois, R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA 1997, 94, 3336-3340.
129. Reddy, B.S.; Hirose, Y.; Lubet, R.; Steele, V.; Kelloff, G.; Paulson, S.; Seibert, K.; Rao, C.V. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000, 60, 293-297.
130. Oshima, M.; Murai, N.; Kargman, S.; Arguello, M.; Luk, P.; Kwong, E.; Taketo, M.M.; Evans, J.F. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001, 61, 1733-1740.
131. Jacoby, R.F.; Seibert, K.; Cole, C.E.; Kelloff, G.; Lubet, R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000, 60, 5040-5044.
132. Sheng, H.; Shao, J.; Kirkland, S.C.; Isakson, P.; Coffey, R.J.; Morrow, J.; Beauchamp, R.D.; DuBois, R.N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997, 99, 2254-2259.
133. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 2007, 356, 2131-2142.
134. Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L.K.; Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342, 1946-1952.
135. Higuchi, T.; Iwama, T.; Yoshinaga, K.; Toyooka, M.; Taketo, M.M.; Sugihara, K. A randomized, doubleblind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin. Cancer Res. 2003, 9, 4756-4760.
136. Phillips, R.K.; Wallace, M.H.; Lynch, P.M.; Hawk, E.; Gordon, G.B.; Saunders, B.P.; Wakabayashi, N.; Shen, Y.; Zimmerman, S.; Godio, L.; Rodrigues-Bigas, M.; Su, L.K.; Sherman, J.; Kelloff, G.; Levin, B.; Steinbach, G.; FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50, 857-860.
137. Baron, J.A.; Cole, B.F.; Sandler, R.S.; Haile, R.W.; Ahnen, D.; Bresalier, R.; McKeown-Eyssen, G.; Summers, R.W.; Rothstein, R.; Burke, C.A.; Snover, D.C.; Church, T.R.; Allen, J.I.; Beach, M.; Beck, G.J.; Bond, J.H.; Byers, T.; Greenberg, E.R.; Mandel, J.S.; Marcon, N.; Mott, L.A.; Pearson, L.; Saibil, F.; van Stolk, R.U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003, 348, 891-899.
138. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302, 649-658.
139. Baron, J.A.; Sandler, R.S.; Bresalier, R.S.; Quan, H.; Riddell, R.; Lanas, A.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Loftus, S.; Morton, D.G. Approve Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131, 1674-1682.
140. Bertagnolli, M.M.; Eagle, C.J.; Zauber, A.G.; Redston, M.; Breazna, A.; Kim, K.; Tang, J.; Rosenstein, R.B.; Umar, A.; Bagheri, D.; Collins, N.T.; Burn, J.; Chung, D.C.; Dewar, T.; Foley, T.R.; Hoffman, N.; Macrae, F.; Pruitt, R.E.; Saltzman, J.R.; Salzberg, B.; Sylwestrowicz, T.; Hawk, E.T. Adenoma Prevention with Celecoxib Study Investigators. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev. Res. 2009, 4, 310-321.
141. Konturek, P.C.; Rembiasz, K.; Burnat, G.; Konturek, S.J.; Tusinela, M.; Bielanski, W.; Rehfeld, J.; Karcz, D.; Hahn, E. Effects of cyclooxygenase-2 inhibition on serum and tumour gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig. Dis. Sci. 2006, 51, 779-787.
142. Becerra, C.R.; Frenkel, E.P.; Ashfaq, R.; Gaynor, R.B. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. Int. J. Cancer 2003, 105, 868-872.
143. Chulada, P.C.; Thompson, M.B.; Mahler, J.F.; Doyle, C.M.; Gaul, B.W.; Lee, C.; Tiano, H.F.; Morham, S.G.; Smithies, O.; Langenbach, R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumourigenesis in Min mice. Cancer Res. 2000, 60, 4705-4708.